The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'.

ABSTRACT:

SUBMITTER: Liuzzo G 

PROVIDER: S-EPMC7717256 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature